Abbonarsi

Circulating Inflammatory-Associated Proteins in the First Month of Life and Cognitive Impairment at Age 10 Years in Children Born Extremely Preterm - 18/04/17

Doi : 10.1016/j.jpeds.2016.09.054 
Karl C.K. Kuban, MD, SMEpi 1, * , Robert M. Joseph, PhD 2, Thomas M. O'Shea, MD, MPH 3, Timothy Heeren, PhD 4, Raina N. Fichorova, MD, PhD 5, Laurie Douglass, MD 1, Hernan Jara, PhD 6, Jean A. Frazier, MD 7, Deborah Hirtz, MD, MD 8, Julie Vanier Rollins, MA 1, Nigel Paneth, MD, MPH 9
on behalf of the

Extremely Low Gestational Age Newborn (ELGAN) Study Investigators*

  List of additional ELGAN Study Investigators is available at www.jpeds.com (Appendix).

1 Department of Pediatrics, Boston Medical Center, Boston, MA 
2 Department of Anatomy and Neuroanatomy, Boston University School of Medicine, Boston, MA 
3 Department of Pediatrics, Division of Neonatal-Perinatal Medicine, University of North Carolina, Chapel Hill, NC 
4 Department of Biostatistics, Boston University School of Public Health, Boston, MA 
5 Laboratory of Genital Tract Biology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 
6 Department of Radiology, Boston University School of Medicine, Boston, MA 
7 Department of Psychiatry, University of Massachusetts Medical School/ University of Massachusetts Memorial Health Care, Worcester, MA 
8 National Institute of Neurological Disorders and Stroke, Bethesda, MD 
9 Department of Epidemiology and Biostatistics and Pediatrics, Michigan State University, East Lansing, MI 

*Reprint requests: Boston Medical Center, 1 Boston Medical Center Place, Dowling Building, 3-South, Room 3314, Boston, MA 03118.Boston Medical Center1 Boston Medical Center PlaceDowling Building, 3-South, Room 3314BostonMA03118

Abstract

Objectives

To evaluate whether in children born extremely preterm, indicators of sustained systemic inflammation in the first month of life are associated with cognitive impairment at school age.

Study design

A total of 873 of 966 eligible children previously enrolled in the multicenter Extremely Low Gestational Age Newborn Study from 2002 to 2004 were evaluated at age 10 years. We analyzed the relationship between elevated blood concentrations of inflammation-associated proteins in the first 2 weeks (“early elevations”; n = 812) and the third and fourth week (“late elevations”; n = 532) of life with neurocognition.

Results

Early elevations of C-reactive protein, tumor necrosis factor-α, interleukin (IL)-8, intercellular adhesion molecule (ICAM)-1, and erythropoietin were associated with IQ values >2 SD below the expected mean (ORs: 2.0-2.3) and with moderate to severe cognitive impairment on a composite measure of IQ and executive function (ORs: 2.1-3.6). Additionally, severe cognitive impairment was associated with late protein elevations of C-reactive protein (OR: 4.0; 95% CI 1.5, 10), IL-8 (OR: 5.0; 1.9, 13), ICAM-1 (OR: 6.5; 2.6, 16), vascular endothelial growth factor-receptor 2 (OR: 3.2; 1.2, 8.3), and thyroid-stimulating hormone (OR: 3.1; 1.3, 7.3). Moderate cognitive impairment was most strongly associated with elevations of IL-8, ICAM-1, and vascular endothelial growth factor-receptor 2. When 4 or more inflammatory proteins were elevated early, the risk of having an IQ <70 and having overall impaired cognitive ability was more than doubled (ORs: 2.1-2.4); the presence of 4 or more inflammatory protein elevated late was strongly linked to adverse cognitive outcomes (ORs: 2.9-4.8).

Conclusions

Extremely preterm children who had sustained elevations of inflammation-related proteins in the first postnatal month are more likely than extremely preterm peers without such elevations to have cognitive impairment at 10 years.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : BSID-II, CRP, DAS–II, ELGAN, ICAM, IL, LPA, MDI, MMP, NEPSY-II, SAA, TNF, VEGF, VEGF-R2

Keywords : extremely preterm infants, inflammation-related proteins, cognition, school age


Mappa


 Supported by the National Institute of Neurological Disorders and Stroke (5U01NS040069-05 and 2R01NS040069-09) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (5P30HD018655-28). J.F. has received research support from Janssen Research and Development (MENTIS ASD002/CTI500085), SyneuRex International Corp, and Neuren Pharmaceuticals (2014-2016); and she has served on a data safety monitoring board for Forrest Pharmaceuticals. The other authors declare no conflicts of interest.


© 2016  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 180

P. 116 - gennaio 2017 Ritorno al numero
Articolo precedente Articolo precedente
  • 50 Years Ago in The Journal of Pediatrics : Adrenocortical Neoplasms with Hemihypertrophy, Brain Tumors, and Other Disorders
  • Emily B. Heikamp, D. Williams Parsons, Sharon E. Plon
| Articolo seguente Articolo seguente
  • Using Eye Movements to Assess Language Comprehension in Toddlers Born Preterm and Full Term
  • Elizabeth C. Loi, Virginia A. Marchman, Anne Fernald, Heidi M. Feldman

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.